Physician profile
Mathew N Alias
NPI 1508027574
$13,007.20
in general payments reported to CMS, 2019-2025
76 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,171 · 2020: $1,483 · 2021: $1,979 · 2022: $2,065 · 2023: $2,117 · 2024: $1,758 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,276 · Education: $34.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,275.99 |
| Education | $34.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,604.46 | 2021-2025 | Botox, Ubrelvy, Duopa |
| Novartis Pharmaceuticals Corporation | $1,142.31 | 2019-2025 | |
| Biogen, INC. | $793.32 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Teva Pharmaceuticals USA, INC. | $719.31 | 2019-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $554.96 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Allergan, INC. | $526.03 | 2019-2022 | |
| Pfizer INC. | $521.78 | 2019-2025 | |
| Celgene Corporation | $501.85 | 2022-2025 | Zeposia |
| Neurocrine Biosciences, INC. | $407.96 | 2020-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $406.42 | 2019-2025 | Vyepti, Rexulti |
| Amgen INC. | $397.66 | 2019-2025 | Uplizna, Aimovig |
| Medtronic USA, INC. | $358.48 | 2019 | |
| Alexion Pharmaceuticals, INC. | $315.78 | 2019-2025 | Ultomiris, Soliris |
| Supernus Pharmaceuticals, INC. | $309.43 | 2019-2021 | |
| Lilly USA, LLC | $303.72 | 2019-2025 | Amyvid, Kisunla, Emgality |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Alias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.